Abstract
Antitumor effect of UFT against human oral and maxillary cancers was examined clinically and biochemically. UFT therapy was carried out in 26 patients having primary or recurrent tumors in a daily dose of 300-600mg. The average period was 132.1 days and the average dose was 71.4g. UFT therapy was combined with operation and/or radiotherapy in 20 cases, and 6 cases were treated for adjuvant chemotherapy.In preoperative administration, clinical response was observed in one case out of 5 evaluable cases (20%). When UFT therapy was combined with radiotherapy in five cases, tumors were diminished completely in every case. The survival rate of 24 cases was 76.5% in 30 months in those to whom UFT was administered for 4 weeks or more.5-FU levels in the serum and the tumor tissues were examined in 4 cases. 5-FU levels in the tumor tissues were 0.081-0.166 mcg/g and these were reached 6-27 times of the serum one.Side effects were observed in 8 cases (30.8%), mainly digestive symptom, bone marrow supression and liver disfunction. However, these were generally mild, only in 2 cases administration of UFT was stopped due to the side effects.It is considered that UFT can be administered to oral cancer patients usefully and safely.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Japanese Journal of Oral & Maxillofacial Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
